ESPR - Esperion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development171,488147,60357,86829,802
Selling General and Administrative33,09721,37918,28220,238
Non Recurring----
Total Operating Expenses204,585168,98276,15050,040
Operating Income or Loss-204,585-168,982-76,150-50,040
Income from Continuing Operations
Total Other Income/Expenses Net5,5501,9941,172256
Earnings Before Interest and Taxes-204,585-168,982-76,150-50,040
Interest Expense-42-200-400-520
Income Before Tax-201,810-166,988-74,978-49,784
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-201,810-166,988-74,978-49,784
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-201,810-166,988-74,978-49,784
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-201,810-166,988-74,978-49,784